Invesco Pharmaceuticals ETF (PJP)

Key Metrics

TER 0.58% per year

Distribution policy Distributing

Fund size USD 472 M

Inception date June 23, 2005

Holdings 33

Fund currency USD

Fund domicile US

Provider Invesco

For full official fund details, factsheets, and holdings, visit invesco.com (opens in new tab).

Historical Return

Last updated: Oct 15, 2026

1 Year +32.2% +0.9% Div

3 Years (avg.) +19.4% +0.9% Div

5 Years (avg.) +9.7% +0.9% Div

Risk & Analysis Metrics

Last updated: Oct 15, 2026

Volatility

15.73% 1 Year

15.78% 3 Years

16.18% 5 Years

18.20% 10 Years

Max Drawdown

-9.67% 1 Year

-17.00% 3 Years

-18.74% 5 Years

-35.20% 10 Years

Sharpe Ratio

1.40 1 Year

0.87 3 Years

0.37 5 Years

0.26 10 Years

Return Triangle (Heatmap)

Last updated: Oct 15, 2026

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
2011	20.5%	21.0%	30.7%	29.2%	24.0%	15.7%	15.2%	12.5%	11.5%	11.3%	11.5%	10.2%	9.1%	9.0%	10.1%
2012		21.5%	36.1%	32.3%	24.9%	14.8%	14.3%	11.4%	10.4%	10.4%	10.6%	9.3%	8.2%	8.2%	9.4%
2013			52.5%	38.0%	26.0%	13.2%	13.0%	9.8%	8.9%	9.0%	9.5%	8.2%	7.1%	7.2%	8.5%
2014				24.8%	14.5%	2.5%	4.8%	2.8%	2.9%	3.9%	5.1%	4.1%	3.4%	3.8%	5.5%
2015					5.0%	-7.2%	-1.1%	-2.1%	-1.0%	0.8%	2.5%	1.8%	1.2%	1.9%	3.9%
2016						-17.9%	-4.1%	-4.4%	-2.4%	0.0%	2.1%	1.4%	0.8%	1.6%	3.8%
2017							12.1%	3.2%	3.4%	5.0%	6.6%	5.0%	3.8%	4.3%	6.5%
2018								-4.9%	-0.7%	2.8%	5.3%	3.6%	2.4%	3.2%	5.8%
2019									3.6%	6.9%	9.0%	5.9%	4.0%	4.6%	7.5%
2020										10.3%	11.8%	6.6%	4.1%	4.9%	8.1%
2021											13.3%	4.9%	2.1%	3.5%	7.7%
2022												-2.9%	-3.1%	0.5%	6.3%
2023													-3.3%	2.2%	9.6%
2024														8.1%	16.7%
2025															26.0%

Distributions

*by ETF Portfolio Weight Last updated: Oct 15, 2026

Profit Margin Distribution

< 0%

21%

1y 3y N/A N/A

0 - 5%

1y 3y N/A N/A

5 - 10%

21%

1y 3y N/A N/A

10 - 15%

1y 3y N/A N/A

15 - 20%

1y 3y N/A N/A

20 - 30%

17%

1y 3y N/A N/A

30 - 40%

1y 3y N/A N/A

> 40%

1y 3y N/A N/A

P/E Ratio Distribution

< 0

21%

1y 3y N/A N/A

0 - 10

1y 3y N/A N/A

10 - 15

15%

1y 3y N/A N/A

15 - 20

10%

1y 3y N/A N/A

20 - 25

1y 3y N/A N/A

25 - 35

20%

1y 3y N/A N/A

35 - 50

16%

1y 3y N/A N/A

> 50

16%

1y 3y N/A N/A

Discounted Cash Flow

Weighted Average Undervaluation

N/A

Undervalued

> 60%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

15 - 30%

1y 3y N/A N/A

Fair (±15%)

1y 3y N/A N/A

Overvalued

15 - 30%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

> 60%

1y 3y N/A N/A

Market Cap Size Distribution

Micro Cap

0.0%

1y 3y N/A N/A

Small Cap

10.3%

1y 3y N/A N/A

Mid Cap

27.1%

1y 3y N/A N/A

Large Cap

29.0%

1y 3y N/A N/A

Mega Cap

33.5%

1y 3y N/A N/A

Micro: < $300M Small: $300M–$2B Mid: $2B–$10B Large: $10B–$200B Mega: > $200B

Average metrics of all companies in portfolio

Last updated: Oct 25, 2026

Market
Average

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$137B	-
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	1.43%	1.13%
Beta Indicates the relationship between the price performance of a share and the market.	0.55	-
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	35.91	36.21
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything	-85.69	-
Profitable Companies	73%	-
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	807.33	11.65
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	5.27	6.25
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	9.21	6.18

Market
Average

Enterprise Value to EBIT Enterprise Value divided by EBIT	25.49	9.94
Enterprise Value to Revenue Enterprise value divided by revenue	69.09	3.84
Total Debt to Enterprise Value Total debt divided by enterprise value	0.19	0.07
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	0.48	-0.84
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	-1218.27%	25.35%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	-	+52.9%
Return on Equity Equity divided by market cap.	21.71%	36.99%
Return on Assets Indicates a company's profitability in relation to its total assets.	4.34%	14.38%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	9.85%	24.11%

Sectors

Manufacturing	97.1%
Finance and Insurance	2.8%
Other	0.1%

Countries

United States	97.4%
Ireland	2.6%

Limit holdings to companies in a single sector.

$0B >$1T

Ratio between share price and earnings per share. A low ratio could indicate undervaluation.

<0 >50

Ratio of dividends in the last 12 months to current share price.

0% 3%

Revenue increase compared to the same quarter one year ago.

0% 30%

Net income increase compared to the same quarter one year ago.

0% 30%

Profitability of the last quarter.

<-30% >30%

A higher ratio indicates a higher risk. The ratio is difficult to compare between industries.

<0 >3

Discounted cash flow valuation vs. current price. Positive = undervalued, negative = overvalued.

<-50% >+100%

Market Cap

P/E Ratio

Total Investment

Weight

Abbott Laboratories

ABT - Manufacturing

Market Cap $179.44B

P/E Ratio 38.4

Dividends 2.4%

Total Investment $26.78M

Weight 5.67%

Loading details…

Abbvie Inc

ABBV - Manufacturing

Market Cap $832.67T

P/E Ratio 80.5

Dividends 2.4%

Total Investment $25.86M

Weight 5.48%

Loading details…

AMGEN Inc.

AMGN - Manufacturing

Market Cap $237.48B

P/E Ratio 27.1

Dividends 2.3%

Total Investment $25.17M

Weight 5.33%

Loading details…

Johnson & Johnson

JNJ - Manufacturing

Market Cap $833.9B

P/E Ratio 40.0

Dividends 2.0%

Total Investment $24.45M

Weight 5.18%

Loading details…

Merck & Co Inc

MRK - Manufacturing

Market Cap $364.05B

P/E Ratio 115.3

Dividends 2.3%

Total Investment $23.87M

Weight 5.06%

Loading details…

Lilly(Eli) & Co

LLY - Manufacturing

Market Cap $1.2T

P/E Ratio 42.6

Dividends 0.5%

Total Investment $23.69M

Weight 5.02%

Loading details…

Corcept Therapeutics Inc

CORT - Manufacturing

Market Cap $9.57B

P/E Ratio 165.1

Dividends 0.0%

Total Investment $23.43M

Weight 4.96%

Loading details…

Gilead Sciences, Inc.

GILD - Manufacturing

Market Cap $193.48B

P/E Ratio -60.0

Dividends 2.1%

Total Investment $21.38M

Weight 4.53%

Loading details…

Pfizer Inc.

PFE - Manufacturing

Market Cap $171.16B

P/E Ratio 39.7

Dividends 5.7%

Total Investment $21.24M

Weight 4.50%

Loading details…

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

AMRX - Manufacturing

Market Cap $6.51B

P/E Ratio 41.0

Dividends 0.0%

Total Investment $17.69M

Weight 3.75%

Loading details…

Liquidia Corp

LQDA - Manufacturing

Market Cap $3.82B

P/E Ratio 27.2

Dividends 0.0%

Total Investment $17.28M

Weight 3.66%

Loading details…

Travere Therapeutics Inc

TVTX - Manufacturing

Market Cap $4.72B

P/E Ratio -111.3

Dividends 0.0%

Total Investment $15.59M

Weight 3.30%

Loading details…

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

LGND - Manufacturing

Market Cap $6.05B

P/E Ratio 30.3

Dividends 0.0%

Total Investment $15.09M

Weight 3.20%

Loading details…

Regeneron Pharmaceuticals, Inc.

REGN - Manufacturing

Market Cap $87.05B

P/E Ratio 19.2

Dividends 0.5%

Total Investment $14.84M

Weight 3.14%

Loading details…

Harmony Biosciences Holdings Inc

HRMY - Manufacturing

Market Cap $2.1B

P/E Ratio 11.5

Dividends 0.0%

Total Investment $14.46M

Weight 3.06%

Loading details…

Bristol-Myers Squibb Co.

BMY - Manufacturing

Market Cap $814.59B

P/E Ratio 13.5

Dividends 4.1%

Total Investment $13.9M

Weight 2.94%

Loading details…

Viatris Inc

VTRS - Finance and Insurance

Market Cap $20.67B

P/E Ratio -50.0

Dividends 2.7%

Total Investment $13.34M

Weight 2.83%

Loading details…

Jazz Pharmaceuticals plc

JAZZ - Manufacturing

Market Cap $13.89B

P/E Ratio 14.1

Dividends 0.0%

Total Investment $13.16M

Weight 2.79%

Loading details…

Biogen Inc

BIIB - Manufacturing

Market Cap $37.05B

P/E Ratio 44.1

Dividends 0.0%

Total Investment $12.97M

Weight 2.75%

Loading details…

Collegium Pharmaceutical Inc

COLL - Manufacturing

Market Cap $747.48M

P/E Ratio 15.0

Dividends 0.0%

Total Investment $12.94M

Weight 2.74%

Loading details…

Key Metrics

Compare similar ETFs

Historical Return

Risk & Analysis Metrics

Volatility

Max Drawdown

Sharpe Ratio

Return Triangle (Heatmap)

Distributions

Profit Margin Distribution

P/E Ratio Distribution

Discounted Cash Flow

Market Cap Size Distribution

Portfolio Concentration

Latest News

Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast

UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings?

J&J raises its forecast again. CFO Joe Wolk on what's driving it

Average metrics of all companies in portfolio

Sectors

Countries

Stock Screener

Abbott Laboratories

Abbott Laboratories

Abbvie Inc

Abbvie Inc

AMGEN Inc.

AMGEN Inc.

Johnson & Johnson

Johnson & Johnson

Merck & Co Inc

Merck & Co Inc

Lilly(Eli) & Co

Lilly(Eli) & Co

Corcept Therapeutics Inc

Corcept Therapeutics Inc

Gilead Sciences, Inc.

Gilead Sciences, Inc.

Pfizer Inc.

Pfizer Inc.

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Liquidia Corp

Liquidia Corp

Travere Therapeutics Inc

Travere Therapeutics Inc

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Viatris Inc

Viatris Inc

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc

Biogen Inc

Biogen Inc

Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc

Cookie Settings